
#086: Navigating Menopause with MS – Key insights on symptom progression, aging, and personalized care (ECTRIMS Special)
Find out how the menopause affects MS. What new research reveals about progression, symptom management, biological aging and quality of life. You can read the full article here: https://ms-perspektive...
6 Nov 202422min

#085: ECTRIMS Special on innovative MS rehabilitation for better quality of life
New approaches to MS Rehabilitation: From Telerehab to Ocean Sailing and individualized trainings plans for improved wellness. You can read the complete article here: https://ms-perspektive.com/085-ec...
30 Okt 202417min

084: Vascular dysfunction and Multiple Sclerosis. How Your vessels Could Shape Your MS Journey with Dr. Jonathan Pansieri
Dr. Jonathan Pansieri explains how vascular dysfunction could worsen multiple sclerosis and become a target for future treatment approaches. You can read all questions and answers here: https://ms-per...
23 Okt 202448min

#083: ECTRIMS Special on De-escalation and discontinuation of therapies for MS – What does it mean and how can it work?
When can we consider de-escalation or even discontinuation of a high-efficient immunotherapy for MS without risking a disease worsening? You can read the full article on my blog: https://ms-perspektiv...
16 Okt 202433min

#082: Living with neuromyelitis optica (NMO) in Denmark with Leda Bresnov
Leda Bresnov shares her diagnosis, coping strategies, and insights on living with neuromyelitis optica (NMO) in Denmark. You can read all questions and answers on my blog: https://ms-perspektive.com/8...
9 Okt 202439min

#081: Navigating Treatment and Support for MS, NMOSD, and MOGAD in Montenegro with Dr. Sanja Gluscevic
Dr. Sanja V. Gluscevic, a neurologist from Montenegro, specializes in MS, NMOSD and MOGAD, and is dedicated to patient care and advocacy. You can read all questions and answers on my blog: https://ms-...
2 Okt 202445min

#080: B-Cell Depletion – Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) for active RRMS and SPMS, and early PPMS
Learn more about b-cell depletion, including Ocrevus, Kesimpta, Bonspri, Mabthera, Rituxan, and Briumvi, used for active RRMS, SPMS, and PPMS. You can read the full article on my blog: https://ms-pers...
25 Sep 202430min

Special: ECTRIMS 2024 - Personalized MS treatments, genetic risk factors and the benefits of early, effective therapies for women and children
Personalized treatments, genetic risk factors, gender differences and the advantages of early, highly effective therapies. You can read the full article here: https://ms-perspektive.com/ectrims-2024-w...
19 Sep 202419min




















